Clinical Trial

Targeted Prostate Cancer Screening in Men With BRCA1/2 Mutations

Study acronym: IMPACT
Completed
View on ClinicalTrials.gov →
Summary
This interventional study is a follow-up component of the IMPACT project, which aims to identify men at increased hereditary risk of prostate cancer. The study focuses on men carrying BRCA1 and BRCA2 germline mutations and a control group of non-carriers. Participants are contacted by telephone to determine whether they developed prostate cancer during 2025 and to collect updated personal and family medical history information. The goal of the study is to support targeted prostate cancer screening programs in men at higher genetic risk.
Trial Details
NCT Number NCT07416812
Lead Sponsor Institute of Oncology Ljubljana
Conditions Prostate Cancer, Hereditary Prostate Cancer
Enrollment 25 participants
Start Date 2021-03-29
Primary Completion 2021-11-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-18